Life Sciences

  • July 10, 2026

    Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case

    Corcept Therapeutics Inc. lost its bid Friday to have the full Federal Circuit look at a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym.

  • July 10, 2026

    Boston Scientific Top Brass Sued Over Pacemaker Recall

    A Boston Scientific Corp. shareholder has filed a derivative lawsuit against the company's current and former directors and top executives, claiming they ignored early signs of an issue with the company's pacemakers that led to a recall and has been connected to four deaths.

  • July 10, 2026

    Ex-Biomedical Worker Axed For Not Altering Data, Suit Says

    A former regulatory affairs specialist for biomedical company Vitara has alleged in New Jersey state court that she was fired in retaliation for refusing to manipulate data in the company's bid to perform the first human trial of its technology aimed at helping premature newborns.

  • July 10, 2026

    4 Firms Advise On $3.4B Apollo, Bayer Contraceptives Deal

    Apollo Global Management has agreed to pay €3 billion ($3.4 billion) for a minority stake in Bayer's long-acting reversible contraceptive business, according to a joint announcement Friday. 

  • July 09, 2026

    NY AG Says 3M, DuPont Hid PFAS Risks For Years

    The New York attorney general on Thursday sued 3M, DuPont and other major chemical manufacturers in state court alleging that for decades they failed to warn the public about the health risks of forever chemicals in consumer goods like cosmetics and food packaging.

  • July 09, 2026

    VSL Reaches $20M Deal Resolving Knockoff Probiotic Claims

    VSL Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc. and Alfasigma USA Inc. have reached a $20 million settlement with customers who allege they bought a knockoff version of a proprietary probiotic formula for gastrointestinal ailments, according to an order preliminarily approving the deal.

  • July 09, 2026

    Judge Skeptical On Restraining Order In Affirming Care Case

    A D.C. federal judge appeared skeptical Thursday that a Federal Trade Commission case against a gender-affirming care organization must be halted while the group wages a separate case against the commission's investigation into the organization.

  • July 09, 2026

    Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt

    A Federal Circuit panel didn't seem swayed Thursday that ChromaDex's patent infringement suit against Elysium Health had any merit, but the judges struggled to understand why Elysium never tried to dismiss a case it believed was so weak.

  • July 09, 2026

    Regeneron Cites Medtronic Ruling In Amgen Bundling Case

    Regeneron has told a Delaware federal judge there is new reason to preserve its $407 million win against Amgen over cholesterol drug bundling after a California federal judge found in an analogous case that the plaintiff need not prove the defendant had monopoly power over every item in a bundle.

  • July 09, 2026

    Sandoz's Patent Loss Blocks Antitrust Suit, 4th Circ. Told

    Retired U.S. Circuit Judge Paul R. Michel is backing Amgen against Sandoz's Fourth Circuit appeal, arguing in an amicus brief that the final say over now-nixed allegations of blocked biosimilar competition to arthritis drug Enbrel came when Amgen successfully sued Sandoz for patent infringement.

  • July 09, 2026

    Fed. Circ. Affirms AstraZeneca Win Over $107.5M Verdict

    The Federal Circuit on Thursday upheld a lower court's invalidation of a pair of cancer drug patents that a jury found AstraZeneca infringed, turning back a Pfizer unit's attempt to revive a $107.5 million verdict.

  • July 09, 2026

    Actavis Can't Escape State AG Generic Drug Claims

    A Connecticut federal court has trimmed several claims from state enforcers accusing Actavis of fixing prices for dermatology drug products but allowed most of the claims against the drugmaker to proceed.

  • July 09, 2026

    Sam's Club Reaches Deal With Ex-Worker In Miscarriage Suit

    Sam's Club and a former employee who alleged she suffered a miscarriage after the retailer failed to accommodate work restrictions related to her attempt to become pregnant through in vitro fertilization have reached a settlement.

  • July 08, 2026

    Jazz Patent Suit Over Xyrem Survives Dismissal In NJ

    A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolepsy drug Xyrem infringes a series of patents.

  • July 08, 2026

    AstraZeneca Employee Traded On Icosavax Deal, SEC Says

    The U.S. Securities and Exchange Commission on Wednesday accused a former AstraZeneca Pharmaceuticals LP employee of using nonpublic information to trade ahead of the company's $1.1 billion acquisition of vaccine design company Icosavax Inc., yielding approximately $10,000 in illicit gains.

  • July 08, 2026

    Pa. Superior Court Upholds J&J Win In Talc Cancer Suit

    The Pennsylvania Superior Court on Tuesday upheld a 2025 verdict clearing Johnson & Johnson of liability in a suit alleging that using talc caused a woman's fatal mesothelioma, finding that a lower court didn't err by clarifying the jury's instructions after jurors awarded $22 million in punitive damages.

  • July 08, 2026

    Formula-Maker Sued After Recall And Reports Of Sick Infants

    Infant formula manufacturer Nara Organics Inc. sold milk-based powder that had to be recalled after federal regulators learned that multiple infants who had consumed the product were hospitalized with life-threatening botulism, according to a proposed class action filed Wednesday in New York federal court.

  • July 08, 2026

    PBMs Fight Bid To Add Pharmacy Group To Price-Fixing Suit

    Two pharmacy benefit managers have told a Michigan federal judge that a trade association for small pharmacies should not be allowed to intervene in a price-fixing lawsuit brought by the state's attorney general.

  • July 08, 2026

    Sheppard Adds Transactional, IP Attys In Chicago And San Diego

    Sheppard announced Wednesday that the firm has added an experienced intellectual property attorney focused on life sciences as a San Diego area-based partner, a day after announcing the addition of two Chicago-based transactional partners.

  • July 08, 2026

    Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

    Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.

  • July 08, 2026

    Biggest Rulings For Patent Attys In 2026: A Midyear Report

    The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.

  • July 07, 2026

    2 Ex-Telehealth Execs Sentenced For $100M Adderall Scheme

    A California federal judge on Tuesday sentenced two former executives of a telehealth company who were convicted of operating a $100 million scheme to illegally distribute Adderall over the internet, fining them $1 million each and giving the founder six years in prison.

  • July 07, 2026

    Illinois Cases To Watch In 2026: Midyear Report

    Mead Johnson is set to go to trial this summer in the first case to make it to a jury in multidistrict litigation claiming baby formula caused a serious gut illness in premature infants, while the U.S. attorney's office in Chicago is facing a possible sanctions hearing over prosecutorial misconduct allegations in two Illinois cases on attorneys' radar for the rest of the year.

  • July 07, 2026

    Regeneron Ducks Amgen's Eylea Antitrust Counterclaims

    A West Virginia federal judge dismissed key counterclaims and defenses Tuesday that Amgen had raised against Regeneron's patent infringement lawsuit targeting bids by multiple would-be rivals to produce biosimilar versions of eye medication Eylea, preserving only arguments that Regeneron waited too long to pursue the patent.

  • July 07, 2026

    CEO Cops To Conspiracy In BigLaw Insider Trading Case

    A Dubai-based CEO and trader has pled guilty in Massachusetts federal court to charges that he worked with a former BigLaw associate and others to carry out a far-reaching insider trading scheme.

Expert Analysis

  • Opinion

    AI Presents A Make-Or-Break Moment For Outside Counsel

    Author Photo

    The rapid adoption of artificial intelligence by corporate legal departments is forcing a long-overdue reset of the relationship between inside and outside counsel, and introducing a significant opportunity to shed frustrating inefficiencies and strengthen collaboration for firms willing to embrace the shift, says Intel Chief Legal Officer April Miller Boise.

  • Opinion

    USPTO Has A Chance To Correct Double-Patenting Doctrine

    Author Photo

    Now that the issue of obviousness-type double patenting is front and center before the U.S. Patent and Trademark Office's Appeals Review Panel, the agency should put an end to the practice of rejecting earlier-expiring patents in favor of later-expiring ones, say attorneys at Orrick.

  • Navigating Life Sciences Deals Amid Heightened Scrutiny

    Author Photo

    With pricing reform initiatives, national security legislation and evolving trade policy currently contributing to meaningful uncertainty for life sciences companies, it is important to proactively structure deals to avoid downstream complications, say attorneys at Cooley.

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.